As of Nov 25
| +0.17 / +0.97%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 25.00, with a high estimate of 28.00 and a low estimate of 7.00. The median estimate represents a +41.64% increase from the last price of 17.65.
The current consensus among 7 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.